NCT01688960View on ClinicalTrials.gov

"Nesvacumab (REGN910/ SAR307746) and Aflibercept (Ziv-aflibercept in the U.S.) in Patients With Advanced Solid Malignancies"

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Solid Tumors

Interventions

DRUG

nesvacumab (REGN910/ SAR307746)

Dose level 1

DRUG

nesvacumab (REGN910/ SAR307746)

Dose level 2

DRUG

nesvacumab (REGN910/ SAR307746)

Dose level 3

DRUG

aflibercept (ziv-aflibercept)

Dose level 1

DRUG

aflibercept (ziv-aflibercept)

Dose level 2

Trial Locations (6)

Unknown

Indianapolis

New York

Oklahoma City

Philadelphia

San Antonio

Toronto

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT01688960 - "Nesvacumab (REGN910/ SAR307746) and Aflibercept (Ziv-aflibercept in the U.S.) in Patients With Advanced Solid Malignancies" | Biotech Hunter | Biotech Hunter